

MEDISINSK LABORATORIUM

OSL&HELSE Uniogen

Evaluation of analytical and clinical performances of the second generation GenomEra® SARS-CoV-2 Assay Kit

Amir MogghadamFürst Medisinsk Laboratorium, Oslo, NorwayKambiz Persley, Atiq FaramarzOslo Helse Testsenter, Oslo, NorwayJiri Vainio, Antti-Heikki Tapio, Jari J. MartelinAbacus Diagnostica – part of Uniogen, Turku, Finland


BACKGROUND AND MATERIALS

Background

- Reliable, robust, and easy-to-use molecular testing for SARS-CoV-2 remains a critical element in the global strategy to control COVID-19.
- Aim of the study was to evaluate the analytical and clinical performance of the GenomEra SARS-CoV-2 2.0 Assay Kit.

Materials and methods

- Analytical sensitivity was assessed using two inactivated SARS-CoV-2 standards.
- Analytical specificity was determined by *in vitro* testing using a panel of potentially cross-reactive microbes at high concentration supplemented with *in silico* analysis.
- Clinical performance was evaluated in a clinical microbiology laboratory and a SARS-CoV-2 testing center based in Norway.
 - A total of 102 clinical specimens (20 saliva and 82 naso-/oropharyngeal swabs) collected in Oslo, Norway during October-December 2021.
 - Reference assays: RIDA®GENE SARS-CoV-2 (R-Biopharm AG, Germany) DirectDetect[™] SARS-CoV-2 Detection Kit (Covote Bioscience, China)



Sample preparation protocol of the GenomEra SARS-CoV-2 2.0 Assay Kit.

RESULTS

Analytical sensitivity - Limit of Detection (LoD)

- First WHO International Standard for SARS-CoV-2 RNA: 250 IU/mL
- NATtrol[™] SARS-Related Coronavirus 2 (SARS-CoV-2) Stock: **500 copies/mL**

Analytical specificity

• No cross-reactivity was detected in vitro or in silico

Clinical performance

- Clinical sensitivity: 100% (CI95: 93.2-100%)
- Clinical specificity: **100%** (CI95: 92.9-100%)
- Technical successful rate: **97.1%** (99/102)

Organism	Result		
Human coronavirus 229E	Negative		
Human coronavirus 0C43	Negative		
Human coronavirus HKU1	Negative		
Human coronavirus NL63	Negative		
SARS-CoV-1	Potentially positive for E gene target ¹		
MERS-CoV	Negative		
Influenza A	Negative		
Influenza B	Negative		
Respiratory syncytial virus A	Negative		
Respiratory syncytial virus B	Negative		
Legionella pneumophila	Negative		

¹ The primers and the probe for E gene are not exclusively specific for SARS-CoV-2 and may also detect SARS coronavirus (SARS-CoV-1) especially when present in high copy numbers.

GenomEra SARS-CoV-2 2.0 Assay Kit	Reference assays		PPA %	NPA %
	Positive	Negative	(CI 95)	(CI 95)
Positive	52	0	100 (93.2–100)	100 (92.9–100)
Negative	0	50		

CONCLUSION

- The GenomEra SARS-CoV-2 2.0 Assay Kit provides a rapid and accurate method for COVID-19 testing
- Comparable performance with conventional real-time RT-PCR methods
- Short turnaround time
- Time-to-result: 55 minutes for 1-4 samples
- <5 min hands-on time
- 50 min assay run time
- Suitable for small and medium-sized laboratories not necessarily having a specialist in molecular biology





This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 101016203.

